Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity

Rhea-AI Filing Summary

Amneal Pharmaceuticals director John Kiely reported two transactions in Class A Common Stock on 2026-08-13. He sold 50,000 shares at a weighted average price of $17.64 per share in multiple trades within a $17.26–$17.88 range, and separately donated 10,000 shares as a charitable gift to a donor advised fund.

Insider Trade Summary

Net Seller: 60,000 shares

Net Sell 2 txns

Insider Kiely John

Role Director

Sold 50,000 shs ($882K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1	50,000	$17.64	$882K
Gift	Class A Common Stock F2	10,000	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 200,252 shares (Direct)

Footnotes (2)

1. F1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.26 to $17.88 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
2. F2. Represents a charitable donation of common stock to a donor advised fund.

Key Figures

Shares sold: 50,000 shares Weighted average sale price: $17.64 per share Sale price range: $17.26–$17.88 per share +1 more

4 metrics

Shares sold 50,000 shares Class A Common Stock sale on 2026-08-13

Weighted average sale price $17.64 per share Open-market sale of 50,000 shares

Sale price range $17.26–$17.88 per share Prices for multiple sale transactions on 2026-08-13

Charitable gift shares 10,000 shares Bona fide gift of Class A Common Stock on 2026-08-13

Key Terms

weighted average price, bona fide gift, donor advised fund

3 terms

weighted average price financial

"The price included is a weighted average price for multiple transactions."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

bona fide gift financial

"Transaction code G is described as a bona fide gift."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

donor advised fund financial

"Represents a charitable donation of common stock to a donor advised fund."

A donor advised fund is a charitable savings account you fund with cash or assets (including stocks) that lets you take an immediate tax benefit while recommending when and which charities receive grants over time. Think of it like a dedicated piggy bank for giving: you get tax relief when you put money in, can avoid selling appreciated securities and triggering capital gains, and still control the timing and recipients of donations, which affects tax planning, portfolio decisions, and public giving signals.

FAQ

What insider transactions did AMRX director John Kiely report on this Form 4?

John Kiely reported two transactions in Amneal Pharmaceuticals (AMRX) Class A stock on 2026-08-13: an open-market sale of 50,000 shares and a separate charitable gift of 10,000 shares to a donor advised fund.

How many AMRX shares did John Kiely sell and at what price?

John Kiely sold 50,000 AMRX shares at a weighted average price of $17.64 per share. The filing states the trades occurred in multiple transactions with prices ranging from $17.26 to $17.88 per share.

Did John Kiely make any charitable donations of AMRX stock in this filing?

Yes. The Form 4 reports that John Kiely made a charitable donation of 10,000 shares of Amneal Pharmaceuticals Class A Common Stock. The gift is described as a contribution to a donor advised fund with no per-share price reported.

Were the AMRX stock sales by John Kiely under a Rule 10b5-1 trading plan?

The Form 4 does not state that these trades were made under a Rule 10b5-1 trading plan. The document-level 10b5-1 checkbox is not marked as affirming plan use, and the bound footnotes do not reference any trading plan.

What does the weighted average sale price mean in John Kiely’s AMRX Form 4?

The Form 4 explains that $17.64 is a weighted average price for multiple trades. It notes that individual sale prices for the 50,000 shares ranged between $17.26 and $17.88, and that detailed trade-level pricing information is available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 04:32 PM Accepted by SEC EDGAR 08/14/2026 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kiely John

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/13/2026		S		50,000	D	$17.64(1)	210,252	D
Class A Common Stock	08/13/2026		G		10,000	D	$0(2)	200,252	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.26 to $17.88 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

2. Represents a charitable donation of common stock to a donor advised fund.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)